OUR MISSION 

MISSION : Alpha-1 Biologics was founded by Cynthia L. Bristow, PhD, in June, 2011 for the purpose of developing patented biotechnology related to the generation of immune cells from stem cells within the body to treat immunodeficiency with the following disease applications: 

· Immune cell replenishment (cancer therapy, HIV/AIDS) 

· HDL and LDL regulation (cardiovascular disease) 

IMPLEMENTATION OF MISSION : The discoveries at the core of Alpha-1 Biologics biotechnology resulted from basic research conducted by Bristow and supported for many years by the non-profit research organization, Institute for Human Genetics and Biochemistry (IHGB) funded by the Harry Winston Research Foundation.

Disease applications:

• Immune cell replenishment (cancer therapy, HIV/AIDS) 

• HDL and LDL regulation (cardiovascular disease) 

Funding by:

• Institute for Human Genetics and Biochemistry (IHGB) and the Harry Winston Research Foundation.